Diaxonhit SA Share Price Euronext Paris
Equities
ALEHT
FR0004054427
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
05-08 | Eurobio Scientific: agreement with Myriad Genetics | CF |
05-08 | Eurobio Scientific to Buy Gene Expression Test for Breast Cancer | MT |
Sales 2024 * | 138M 148M 11.63B | Sales 2025 * | 148M 159M 12.48B | Capitalization | 150M 162M 12.68B |
---|---|---|---|---|---|
Net income 2024 * | 9M 9.67M 758M | Net income 2025 * | 11M 11.82M 927M | EV / Sales 2024 * | 1.02 x |
Net cash position 2024 * | 9.9M 10.64M 834M | Net cash position 2025 * | 32.8M 35.25M 2.76B | EV / Sales 2025 * | 0.79 x |
P/E ratio 2024 * |
15.8
x | P/E ratio 2025 * |
12.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61.33% |
Managers | Title | Age | Since |
---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | - | 18/06/17 |
Director of Finance/CFO | 43 | 30/09/22 | |
Cathie Marsais
COO | Chief Operating Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | - | 18/06/17 |
Director/Board Member | 68 | 03/11/09 | |
Director/Board Member | 67 | 14/06/17 |
1st Jan change | Capi. | |
---|---|---|
+49.21% | 56.87B | |
+36.25% | 39.72B | |
-6.86% | 39.27B | |
-4.42% | 28.73B | |
+12.00% | 26.21B | |
-18.27% | 19.79B | |
+29.57% | 12.28B | |
+25.41% | 12.23B | |
-0.35% | 12.12B |
- Stock Market
- Equities
- ALERS Stock
- ALEHT Stock